Author: Athira Sudhakaran  – Statistical Programmer at Genpro

Enrichment trials use patient characteristic to select a study population in which detection of a drug effect is more likely than it would be in an unselected population.

There are three categories of enrichment strategies for Clinical Trial:

  • Strategies to decrease heterogeneity
  • Prognostic enrichment strategies in clinical trial
  • Predictive enrichment strategies in clinical trial

Strategies to Decrease Heterogeneity

There are many commonly used strategies to decrease subject heterogeneity including carefully defining inclusion and exclusion criteria, using placebo lead-in periods to eliminate patients that improve spontaneously or excluding patients taking pharmacologically similar drugs. Excluding patients with a comorbid illness that would make completing the treatment period unlikely will also help to reduce variability.

Prognostic Enrichment Strategies in Clinical Trial

Prognostic enrichment is the selection of patients that are more likely to have a specific, disease‑related endpoint.  The guidance points out that to properly power a study, the sample size needs to be based on the “effect size and event rate in the placebo group”.  Prognostic enrichment will allow an increase in the absolute effect size while keeping the relative effect the same.  Examples of prognostic enrichment strategies include clinical and laboratory measures and gene expression profiles. These measurements predict the prognosis of the patients, but not the predictive value of drug efficacy.

Predictive Enrichment Strategies in Clinical Trial

Predictive enrichment in clinical trial is the identification and enrolment of patients that are likely to respond to the study drug. Predictive enrichment increases both the absolute and relative effect of the study drug. Pre-randomization screening for responders and screening for proteomic or genomic markers related to a drug’s mechanism of action are an example of predictive enrichment strategies.

Genpro Experience

In one of the device studies, we have worked to evaluate the performance of an automated device for the detection of diabetic retinopathy. At the start of the study, all participants with diabetes who met inclusion and exclusion criteria were enrolled. Then later to avoid excessive enrolment in any one stratum (no/mild, moderate DR, or vision-threatening DR), the totals monitored monthly and the study population enriched to ensure sufficient numbers of subjects with more than mild DR. Patient enrichment was targeted based on elevated HbA1C or fasting blood glucose (FBG), factors which have been shown to be correlated with higher rates of vision-threatening DR among patients with diabetes.

Wish to know more? Feel free to write to us at info@genproindia.com.

You may also like:
SAS Index – Make Subsetting Quick

Author: Dinesh Motkar – Clinical SAS Programmer at Genpro As part of SAS programming, we often come across situations where we need to remove unwanted data or to locate specific rows from data. Performing this processing using where clause or statement along with index can...

Read More
Introduction to Linear Mixed Model

Introduction to Linear Mixed Model   Author: Anoop Jose – Clinical SAS Programmer at Genpro Research In clinical trials, usually, we take multiple measurements from a subject at different time points. In the case of repeated measures or longitudinal data, multiple observations are collected from...

Read More
Clinical Data and Wearable Device: Future of Data Capturing

Clinical Data and Wearable Device: Future of Data Capturing   Author: Mr. Vinu C Raju – Clinical Statistical Programmer at Genpro Have you ever wondered how your social networking app is suggesting a friend request for a person you met yesterday in a get together? ...

Read More
Our Products